Nuclera extends Series C funding to advance antibody engineering
Investment to accelerate development of full‑format antibody capabilities on eProtein Discovery system
Read More
Author: John Pinching
Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
New manufacturing technologies aim to accelerate next-generation cell therapy development
Read More
Fabentech secures French approval for Ricimed antidote
Authorisation marks major step in European preparedness against ricin
Read More
Oxford Drug Design reports major in vivo milestone for novel cancer therapy
Data shows potential route to overcoming resistance in aggressive colorectal tumours
Read More
Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
Partnership will analyse m6A RNA modifications in patient samples to support development of STC‑15
Read More- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
